Clinafloxacin for the treatment of bacterial endocarditis

Clinical Infectious Diseases

Volumn 38, Issue 5, 2004, Pages 620-631

  Levine, Donald P ^a,d   Holley, H Preston ^b   Eiseman, Irene ^b   Willcox, Paul ^c   Tack, Kenneth ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINAFLOXACIN; QUINOLONE DERIVATIVE;

ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; BACTERIAL ENDOCARDITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; FEMALE; HEART VALVE; HEART VALVE PROSTHESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; POPULATION; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; TISSUE CULTURE; INFECTION; MICROBIOLOGY; MULTICENTER STUDY; PATHOPHYSIOLOGY; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ADULT; ENDOCARDITIS, BACTERIAL; FEMALE; FLUOROQUINOLONES; HEART VALVE PROSTHESIS; HUMANS; MALE; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 1442278313     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381670     Document Type: Article

References (56)

1. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 1995; 274:1706-13.
2. Cremieux AC, Maziere B, Vallois JM, et al. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis 1989; 159:938-44.
3. Cremieux AC, Saleh-Mghir A, Vallois JM, et al. Efficacy of temafloxacin in experimental Streptococcus adjacens endocarditis and autoradiographic diffusion pattern of [14C] temafloxacin in cardiac vegetations. Antimicrob Agents Chemother 1992; 36:2216-21.
4. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7.
5. Klepser ME, Ernst EJ, Petzold CR, Rhomberg P, Doern GV. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob Agents Chemother 2001; 45:673-8.
6. Winston DJ, Lazarus HM, Beveridge RA, et al. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 2001; 32:381-90.
7. Barrett MS, Jones RN, Erwin ME, Johnson DM, Briggs BM. Antimicrobial activity evaluations of two new quinolones, PDI2739I (CI-960 and AM-1091) and PD131628. Diagn Microbiol Infect Dis 1991; 14:389-401.
8. Forstall GJ, Knapp CC, Washington JA. Activity of new quinolones against ciprofloxacin-resistant staphylococci. Antimicrob Agents Chemother 1991; 35:1679-81.
9. Cohen MA, Yoder SL, Huband MD, Roland GE, Courtney CL. In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci. Antimicrob Agents Chemother 1995; 39:2123-7.
10. Kaatz GW, Seo SM, Lamp KC, Bailey EM, Rybak MJ. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1992; 36:1192-7.
11. Tack KJ, McGuire NM, Eiseman IA. Initial clinical experience with clinafloxacin in the treatment of serious infections. Drugs 1995; 49(Suppl 2):488-91.
12. Solomkin JS, Wilson SE, Christou NV, et al. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections. Ann Surg 2001; 233:79-87.
13. Glauser MP, Brennscheidt U, Cornely O, et al. Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients. Clin Microbiol Infect 2002; 8:14-25.
14. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994; 96:200-9.
15. Babinchak TJ. Oral ciprofloxacin therapy for prosthetic valve endocarditis due to Actinobacillus actinomycetemcomitans. Clin Infect Dis 1995; 21:1517-8.
16. Uzun O, Akalin HE, Unal S, Demircin M, Yorgancioglu AC, Ugurlu B. Long-term oral ciprofloxacin in the treatment of prosthetic valve endocarditis due to Pseudomonas aeruginosa. Scand J Infect Dis 1992; 24:797-800.
17. Barnass S, Holland K, Tabaqchali S. Vancomycin-resistant Corynebacterium species causing prosthetic valve endocarditis successfully treated with imipenem and ciprofloxacin. J Infect 1991; 22:161-9.
18. Anderson MD, Miller LK. Endocarditis due to Neisseria mucosa. Clin Infect Dis 1993; 16:184.
19. Yebra M, Ortigosa J, Albarran F, Crespo MG. Ciprofloxacin in a case of Q fever endocarditis. N Engl J Med 1990; 323:614.
20. Cacoub P, Wechsler B, Chapelon C, Thibon M, Godeau P. Q-fever endocarditis and treatment with the fluoroquinolones. Arch Intern Med 1991; 151:816, 818.
21. Sacher HL, Miller WC, Landau SW, Sacher ML, Dixon WA, Dietrich KA. Relapsing native-valve enterococcal endocarditis: a unique cure with oral ciprofloxacin combination drug therapy. J Clin Pharmacol 1991; 31:719-21.
22. Dawson SJ, White LA. Treatment of Haemophilus aphrophilus endocarditis with ciprofloxacin. J Infect 1992; 24:317-20.
23. Micozzi A, Venditti M, Gentile G, Alessandri N, Santero M, Martino P. Successful treatment of Brucella melitensis endocarditis with pefloxacin. Eur J Clin Microbiol Infect Dis 1990; 9:440-2.
24. Nettles RE, Sexton DJ. Successful treatment of Edwardsiella tarda prosthetic valve endocarditis in a patient with AIDS. Clin Infect Dis 1997; 25:918-9.
25. Brown NM, Korner RJ, Zollman CE, Martin RP, Millar MR. Ciprofloxacin treatment of bacterial endocarditis involving prosthetic material after cardiac surgery. Arch Dis Child 1997; 76:68-9.
26. Tebas P, Martinez Ruiz R, Roman F, et al. Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis. J Infect Dis 1991; 163:204-5.
27. MacGowan AP, Reeves DS, Wright C, Glover SC. Tricuspid valve infective endocarditis and pulmonary sepsis due to Erysipelothrix rhusiopathiae successfully treated with high doses of ciprofloxacin but complicated by gynaecomastia. J Infect 1991; 22:100-1.
28. Rambaldi M, Ambrosone L, Migliaresi S, Rambaldi A. Combination of co-trimoxazole and ciprofloxacin as therapy of a patient with infective endocarditis caused by an enterococcus highly resistant to gentamicin. J Antimicrob Chemother 1997; 40:737-8.
29. Tripodi MF, Locatelli A, Adinolfi LE, Andreana A, Utili R. Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicin-resistant enterococci. Eur J Clin Microbiol Infect Dis 1998; 17:734-6.
30. Mehta NJ, Khan IA, Mehta RN, Gulati A. Stenotrophomonas maltophilia endocarditis of prosthetic aortic valve: report of a case and review of literature. Heart Lung 2000; 29:351-5.
31. Binder D, Zbinden R, Widmer U, Opravil M, Krause M. Native and prosthetic valve endocarditis caused by Rothia dentocariosa: diagnostic and therapeutic considerations. Infection 1997; 25:22-6.
32. Eckart RE, Hospenthal DR, Fishbain JT. Response of complicated methicillin-resistant Staphylococcus aureus endocarditis to the addition of trovafloxacin. Pharmacotherapy 2000; 20:589-92.
33. Goerre S, Malinverni R, Aeschbacher BC. Successful conservative treatment of nontyphoid salmonella endocarditis involving a bioprosthetic valve. Clin Cardiol 1998; 21:368-70.
34. Giamarellou H, Galanakis N. Use of intravenous ciprofloxacin in difficult-to-treat infections. Am J Med 1987; 82:346-51.
35. Giamarellou H, Perdikaris G, Galanakis N, Davoulos G, Mandragos K, Sfikakis P. Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative bacterial infections. Antimicrob Agents Chemother 1989; 33:1362-7.
36. Daikos GL, Kathpalia SB, Lolans VT, Jackson GG, Fosslien E. Long-term oral ciprofloxacin: experience in the treatment of incurable infective endocarditis. Am J Med 1988; 84:786-90.
37. Chin NX, Clynes N, Neu HC. Resistance to ciprofloxacin appearing during therapy. Am J Med 1989; 87:28S-31S.
38. Fass RJ, Plouffe JF, Russell JA. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. Am J Med 1989; 87:164S-8S.
39. Gudiol F, Cabellos C, Pallares R, Linares J, Ariza J. Intravenous ciprofloxacin therapy in severe infections. Am J Med 1989; 87:221S-4S.
40. Levy PY, Drancourt M, Etienne J, et al. Comparison of different antibiotic regimens for therapy of 32 cases of Q fever endocarditis. Antimicrob Agents Chemother 1991; 35:533-7.
41. Raoult D, Yeaman MR, Baca OG. Susceptibility of Coxiella burnetii to pefloxacin and ofloxacin in ovo and in persistently infected L929 cells. Antimicrob Agents Chemother 1989; 33:621-3.
42. Raoult D, Houpikian P, Tissot Dupont H, Riss JM, Arditi-Djiane J, Brouqui P. Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med 1999; 159:167-73.
43. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 1989; 2(8671):1071-3.
44. Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996; 101:68-76.
45. Schmitz FJ, Fluit AC, Milatovic D, Verhoef J, Heinz HP, Brisse S. In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2000; 46:109-13.
46. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982; 97:496-503.
47. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674-80.
48. Rice LB, Calderwood SB, Eliopoulos GM, Farber BF, Karchmer AW. Enterococcal endocarditis: a comparison of prosthetic and native valve disease. Rev Infect Dis 1991; 13:1-7.
49. Chaudhry R, Mathur P, Dhawan B, Gaur S, Dey AB. Infections caused by Gemella spp: case reports from India. J Infect 2001; 43:152-5.
50. La Scola B, Raoult D. Molecular identification of Gemella species from three patients with endocarditis. J Clin Microbiol 1998; 36:866-71.
51. Yu VL, Fang GD, Keys TF, et al. Prosthetic valve endocarditis: superiority of surgical valve replacement versus medical therapy only. Ann Thorac Surg 1994; 58:1073-7.
52. Grover FL, Cohen DJ, Oprian C, Henderson WG, Sethi G, Hammermeister KE. Determinants of the occurrence of and survival from prosthetic valve endocarditis: experience of the Veterans Affairs Cooperative Study on Valvular Heart Disease. J Thorac Cardiovasc Surg 1994; 108:207-14.
53. Tornos P, Sanz E, Permanyer-Miralda G, Almirante B, Planes AM, Soler-Soler J. Late prosthetic valve endocarditis: immediate and long-term prognosis. Chest 1992; 101:37-41.
54. Kalmar P, Goecke N, Kraas E, Menzel T. Pharmacokinetic behavior of ciprofloxacin both in native cardiac and porcine valves treated in glutaraldehyde. Diagn Microbiol Infect Dis 1990; 13:115-26.
55. Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2000; 45:363-5.
56. Ribera A, Jurado A, Ruiz J, et al. In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine. Diagn Microbiol Infect Dis 2002; 42:123-8.